An autoantibody from a patient with lupusoverlap syndrome was found to bind a specific region of U1 RNA. By using RNA sequence analysis, immunoprecipitation, and competition experiments with in vitro synthesized fragments of U1 RNA, a region of 40 nucleotides representing a stem-oop secondary structure was found to be an immunoreactive domain. This antibody recognized a conformational epitope because neither the RNA stem nor the RNA loop alone was immunoprecipitable. Antisense Ul RNA, U1 DNA, and other small RNAs were not reactive with the antibody. While the origins of nucleic acid-binding antibodies are unknown, this RNA-specific autoantibody probably originated by direct presentation to the immune system or as an anti-idiotype against a more common Ul small nuclear ribonucleoprotein-specific autoantibody. Thus, these findings have implications for the mechanisms of autoimmune recognition and provide an immunological approach to probing RNA structure and protein-RNA interactions.
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Nucleic acid-reactive antibodies provide models for the study of protein-nucleic acid interactions (1) (2) (3) (4) (5) . For example, anti-Z-DNA antibodies have been used to probe conformation of DNA and to examine the structure of polytene chromosomes (1, 2) . Although nucleic acids are thought to be poor immunogens (6) , antibodies to nucleic acids have been experimentally induced (5, 7) and have been obtained from sera of autoimmune patients (2, 7, 8) . Most nucleic acidreactive antibodies recognize DNA (1, 2, 4, 5, 8, 9) , although RNA-reactive antibodies that recognize G + C-rich regions (10) , tRNAAIa (11) , and tRNAMet (12) also have been reported. However, antibody binding sites on RNA have not been defined, and these antibodies appear to lack specificity for defined sequences. The high degree of secondary structure of RNA and the known recognition sites of well-characterized RNA binding proteins, such as ribosomal L18 protein (13) and the phage R17 coat protein (14, 15) , suggest that RNA-reactive antibodies may also recognize conformational features of the antigenic molecule. Neither the nature of RNA-antibody recognition nor the mechanism by which nucleic acid-reactive autoantibodies are elicited is understood. We have described RNA-specific autoantibodies (12) that recognize U1 RNA, a small nuclear RNA (snRNA) that is involved in mRNA splicing (16) (17) (18) (19) . U1 RNA is amenable to the study of nucleic acid-protein interactions because ofits small size, the ability to synthesize abundant amounts of the RNA in vitro (20) , and the availability of antibodies that react with U1 ribonucleoproteins (RNPs) (16) . In this study, a contact site on U1 RNA that is specifically recognized by a U1 RNA-reactive autoantibody was determined. This epitope was synthesized in vitro and retained immunological reactivity as long as the conformation of a specific stem-loop structure of Ul RNA was intact. Cells, Labeling, and RNA Preparation. HeLa cells were grown as described (21) . In vivo labeled HeLa cell RNA was prepared by incubating cells in the presence of [32P]orthophosphate at 150 ,uCi/ml (1 Ci = 37 GBq) in phosphate-free medium for 12 hr and processed as described (12) .
MATERIALS AND METHODS
Immunoprecipitations. Immunoprecipitations were performed essentially as described (12, 21, 22) . Immunoprecipitations containing RNA were performed at 4°C in 150 mM NaCl/50 mM Tris, pH 7.4, in the presence of 25 The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. precipitated with antibody were gel-purified and eluted (12), 5' end-labeled (23) , and partially digested in formamide at 100'C for 2 hr. The digestion products were separated by electrophoresis on cellulose acetate (pH 3.5) in the first dimension and homochromatography on DEAE-cellulose in the second dimension as described (24) . Assignments of the predicted nucleotide sequence were deduced by vectoral shift analysis.
Synthesis of U1 RNA Stem-Loop. U1 RNA corresponding to nucleotides 51-90 (stem-loop) and 66-75 (loop) were generated by synthesis of the corresponding DNA oligonucleotides with 5' HindIII and 3' EcoRI linkers by using an Applied Biosystems (Foster City, CA) synthesizer. Purified oligonucleotides were hybridized (25) and cloned into SP64. Construction of the correct insert was verified by plasmid sequencing (26) . The U1 RNA transcripts were synthesized by using the SP6 transcription system after linearization with EcoRI.
RESULTS
Coexistence of Antibodies to RNA and RNP. U1 RNA forms the core of a RNP complex that consists of nine proteins and may never exist as naked RNA in vivo. Three proteins of 70, 30, and 20 kDa recognize specific portions of the RNA (22), while a complex of six proteins (Sm complex) binds a sequence of U1 RNA that is also present in the U2, U4, and U5 snRNAs. Lerner and Steitz (16) first demonstrated that autoantibodies from patients with lupus and related diseases recognize these U1 RNA-binding proteins. The U1 RNP plays an important role in the splicing of precursor mRNA in the nucleus prior to its transport to the cytoplasm (16) (17) (18) (19) .
We have identified three patients that produce antibodies reactive with U1 RNA (12) . In each case, these specificites occurred as a subset of the U1 RNP specificity but appear to be much less common. Serum from a patient with lupusoverlap syndrome and rheumatoid arthritis precipitated U1 and U2 small nuclear RNP (snRNP) complexes by recognition of the associated proteins ( Fig. 1 Upper, lanes 2 and 3) as well as deproteinized U1 RNA from HeLa cells ( Fig. 1 Upper, lanes 7 and 8). Thus, an antibody in the serum, when presented with total cellular RNA, specifically selected the U1 RNA over all other species. The titer of the anti-Ul RNA activity in the patient's serum remained constant over a 2-year period, and no additional RNA reactivities developed ( Fig. 1 Various amounts of the following unlabeled compounds were simultaneously added with 32P-labeled U1 RNA in the immunoprecipitation reactions: *, in vitro synthesized U1 RNA; *, in vitro synthesized antisense U1 RNA; o, oligonucleotide polymers of poly(G, U) and poly(C, U); and v, equimolar poly(G) hybridized to poly(C). (Inset) Autoradiograph of immunoprecipitations after competition with unlabeled U1 RNA. The lanes contained the following amounts of unlabeled competitor U1 RNA: 1, no added RNA; 2, 0.2 ,ug; 3, 1.5 ,ug; 4, 6 ,Lg; 4, 10 ug. block U1 RNA binding by the autoimmune serum indicates that the interaction was highly specific.
To determine whether this antibody recognized only intact U1 RNA or whether a specific region of the molecule was sufficient for binding, 3' portions of the DNA template were deleted. Ul-containing SP64 DNA was cleaved at various restriction enzyme sites represented on the diagram in Fig. 2 Upper, and the resultant DNA templates were used to synthesize the corresponding truncated RNAs. Deletion of the 3' end of U1 RNA did not eliminate recognition by the anti-Ul RNA antibody (Fig. 2 Lower, lanes 2, 4, and 5 bases 75-165 were removed by cutting at the Msp I site (Fig  2 Lower, lane 6) . Thus, transcripts T1 and T2 were precipitable, but transcript T4 was not recognized by the antibody (Fig. 2 Upper) . In each case, the transcripts synthesized before immunoprecipitation and those remaining in the supernatants after immunoprecipitation were examined and found to be of the expected size (data not shown). These results suggested that 49 nucleotides at the 3' end of U1 RNA were not involved in antibody recognition and further eliminated any possibility that extraneous 3' portions of the U1 RNA transcript (165-320) were involved in antibody recognition. To further examine the specificity of the antibody for Ul RNA, other in vitro SP6-synthesized small RNAs, such as U2 RNA (Fig. 2 Lower, lanes 7 and 8) and adenovirusassociated VA RNA (Fig. 2 Lower, lanes 9 and 10) were tested separately and were not recognized by the anti-Ul RNA antibodies. In addition, the antisense Ul RNA of 320 nucleotides was not recognized by the antibody (Fig. 2 Lower, lane 3). These controls also eliminated the influence of 5' promoter/leader sequences of the SP6 transcription system in antibody recognition. Furthermore, singlestranded and double-stranded DNA corresponding to Ul RNA were not precipitable by the anti-Ul RNA antiserum (data not shown).
Determination of Antibody Binding Site on U1 RNA. Because in vitro synthesized fragments of Ul RNA that lacked portions of the 3' end were reactive with the antibody, we determined whether fragments generated by direct RNase digestion could be immunoprecipitated. Thus, Ul RNA was synthesized, digested with RNases T1 and A (Fig. 3 Top, lanes 2-5), and immunoprecipitated with anti-Ul RNA antiserum ( Fig. 3 Top, lanes 7-11). Ul RNA fragments of approximately 40 and 35 nucleotides generated by digestion with RNase T1 were specifically recognized by the antibody (Fig. 3 Top, lanes 8 and 9). Under denaturing conditions the larger of the two major RNase T1 fragments was less precipitable (Fig. 3 Top, lane 9) suggesting that a folded structure of the 40-nucleotide fragment may be required for antibody recognition. The reduced level of material in lane 9 may also reflect loss of the antibody binding the sequence because of nonspecific RNase digestion of the denatured Ul transcript. However, RNase T1 fragments smaller than 35 nucleotides were not precipitable with the antibody (Fig. 3 Top, lane 9). Small RNA fragments resulting from RNase A digestion shown in Fig. 3 Top, lanes 10 and 11, were only poorly recognized by the antibody prior to denaturation. Thus, large nicked fragments of Ul RNA generated by RNase digestion apparently were precipitable with the antibody but separated into multiple small species upon denaturation for PAGE. These findings show that a specific portion of Ul RNA reacts with the autoantibody and suggest that the RNA conformation may affect recognition.
The fragments of Ul RNA immunoprecipitated by the autoantiserum were subjected to RNA sequence analysis. Oligonucleotide fingerprints of the immunoprecipitable T1 fragments labeled at their 5' ends resulted in three unique "wandering spot" patterns as shown in Fig. 3 Middle. The deduced RNA sequences corresponded to nucleotides 51-85 on the Ul RNA molecule. Some guanosine residues remained RNase Ti-resistant, and the 5' ends ofthe oligonucleotides in some cases were degraded. This may have resulted from partial digestion conditions, secondary structural features (27, 28) , or RNase in the polynucleotide kinase used for end-labeling. A proposed secondary structure of Ul RNA (28) and the Ul RNA fragments that are consistent with the deduced patterns of Fig. 3 Middle are diagrammed in Fig. 3 Bottom. The immunoprecipitable fragments of Ul RNA lie within a predicted middle stem-loop (or B loop) of the Ul RNA molecule.
Conformation of the Ul RNA Epitope. To further define the boundaries of the RNA epitope and to determine the nature of the substructure of Ul RNA that is recognized by the antibody, DNA corresponding to just the middle stem-loop B ofUl RNA (nucleotides 51-90) was chemically synthesized and cloned into SP64 (Fig. 2 Upper, SLB). The resulting RNA transcript comprising the stem-loop epitope was efficiently immunoprecipitated with anti-Ul RNA antiserum (Fig. 4 Left, lanes 2 and 6) . Approximately 45% of the input radioactivity in the stem-loop B transcript was precipitable, while that for the entire UI molecule was approximately 60%. As expected, when the 3' half of the stem-loop region was deleted by using Msp I-digested template (Fig. 2 Upper, SLB1; Fig. 3 Bottom), the antibody no longer recognized the RNA transcript (data not shown). These findings confirmed the RNA sequence analysis (Fig. 3) and suggested that either an intact stem-loop structure or the sequence in the 3' end of the stem was required for antibody recognition.
Based upon predicted models of secondary structure for Ul RNA (26, 27) 30 min. Precipitated fragments were gel purified, 5'-end-labeled, and digested in formamide at 100'C for 2 hr. Digestion products were subjected to fingerprint analysis (24) . (Bottom) Model of proposed secondary structure of U1 RNA (27) showing the sequences that were consistent with those immunoprecipitated with the anti-Ul RNA antibody. Fragments 1, 2, and 3 correspond to the wandering spot patterns of U1 RNA deduced in Middle. Fragment 3 corresponds to nucleotides 50-60; fragment 2, 62-73; fragment 1, 72-84. The figure also shows restriction enzyme cleavage sites on the corresponding DNA (Fig. 2 Upper) . A-U-U-G-C-A-C-U-C-C 3') was chemically synthesized (Fig.  2 Upper, LB) and cloned into pSP64. However, the RNA transcript was not recognized by the anti-Ul RNA antibody (Fig. 4 Left, lanes 3 and 7) . The (10) , because G + Crich polymers did not effectively compete for binding to the antibody (Fig. 1 Lower) . Furthermore, the antibody was specific for U1 RNA, since other RNAs and DNAs synthesized in vitro and in vivo were not recognized (data not shown). This antibody differs from other nucleic acidreactive antibodies that are reported to recognize broad classes of RNA or DNA molecules (5, (10) (11) (12) 29 We also showed that disruption of the conformation of the stem-loop B structure of U1 RNA eliminated recognition by this autoantibody. The involvement of RNA conformation in antibody binding is consistent with properties of other known RNA binding proteins (13) (14) (15) . In addition, it has recently been shown that a monoclonal antibody that binds DNA may require a cruciform structure for proper binding (5) . It is interesting to note that the loop B of U1 RNA, which is part of this epitope, is complementary for 11 nucleotides to a region between bases 112 and 125 of U2 RNA. Whether RNA-RNA interactions play a role in the potential association of U1 and U2 snRNPs in the splicing complex is not known. The U1 RNA-specific antibody described here can be used to probe accessible regions in U1 snRNPs and to determine the binding properties of cell proteins associated with snRNAs.
The mechanism by which anti-RNA antibodies are elicited remains obscure. Other than direct immunological presentation, one likely origin is through an idiotype-anti-idiotype networking mechanism (30) (31) (32) , which has been implicated in autoimmune diseases such as myasthenia gravis (32), systemic lupus erythematosus (33), myositis (11), and rheumatoid arthritis (34) . Presentation of a naked U1 RNA to the immune system seems unlikely because RNA is rarely naked in vivo, ribonucleases are abundant in serum, and the response in this patient was to only a limited portion of the molecule. Although direct evidence is not available, our data are compatible with the suggestion that the anti-Ul RNA antibody is anti-idiotypic in origin and was formed against a separate, but more common, Ul RNP autoantibody (idiotype). The idiotypic autoantibody may have been directed against the RNA binding domain of a protein that recognizes the middle stem-loop of Ul RNA. Consistent with this possibility, the serum containing the Ul RNA-specific antibody also contains antibodies against the proteins bound to Ul RNA (35) .
